Humacyte Chief Medical Officer Jeffrey H. Lawson M.D., Ph.D. Elected to Fellowship in the American Surgical Association

Go Back

April 25, 2016

RESEARCH TRIANGLE PARK, N.C. – April 25, 2016 – Humacyte, an innovator in biotechnology and regenerative medicine, announced today that its Chief Medical Officer Jeffrey H. Lawson, M.D., Ph.D., has been elected a Fellow of the American Surgical Association. The newest Fellows, a group of 55 surgeons, were introduced at the 136th Annual Meeting of the American Surgical Association in Chicago, Ill., April 14-16, 2016.

“Jeff is one of the most impressive, experienced and innovative medical professionals I have had the pleasure of working with during my career,” said Carrie S. Cox, Chairman and Chief Executive Officer of Humacyte, Inc. “The entire Humacyte team congratulates Jeff for being selected for this prestigious and elite honor, which is a testament to his unwavering commitment to excellence in the surgical field and his passion for the best possible patient care.”

Dr. Lawson, an American Board of Surgery certified surgeon, was appointed to Chief Medical Officer of Humacyte in October 2015, following a role as clinical advisor to Humacyte over the past 10 years. He has served in various leadership roles at Duke University Medical Center, including Professor of Surgery and Pathology, Vice Chair for Research in Surgery, and Director of Clinical Trials for the Department of Surgery. Dr. Lawson earned his medical degree from the University of Vermont College of Medicine in 1991, and his Ph.D. in Cell and Molecular Biology from the same institution.

“I am honored to have been elected a Fellow of the American Surgical Association, and am most appreciative of this recognition,” said Lawson. “Being a Fellow with this esteemed organization will afford me invaluable professional resources that can help accelerate our work at Humacyte as we research and develop human, tissue-based products.”

Fellowship with the Association is initiated by a current Fellow’s sponsorship of an individual. Each candidate is reviewed by the Association’s entire membership, followed by the Advisory Membership Committee who deliberate and recommend those they believe should be included in the year’s ballot. The Council sets the final ballot, which is then voted by ballot at the American Surgical Association’s Annual Business Meeting.

As a premier academic society for surgeons, the American Surgical Association strives to benefit the patient and the profession of surgery by advocating and promoting excellence, innovation, and integrity in science, education and patient care. Founded in 1880, the Association is the nation’s oldest and most prestigious surgical organization. Its members include the nation’s most prominent surgeons from leading academic and medical institutions. The primary mission of the Association is to be the premier organization for surgical science and scholarship, and to provide a national forum for presenting the developing state of the art and science of surgery.

Visit for more information about the American Surgical Association.

Humacyte plans to begin global Phase III clinical trials of HUMACYL® and the development of future pipeline products which may improve treatment outcomes for patients with a variety of vascular and non-vascular diseases, such as Vascular Trauma, Coronary Artery Bypass, Replacement Trachea and Esophagus, and bypass for Peripheral Arterial Disease.

About Humacyte
Humacyte, Inc., a privately held company founded in 2004, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications, with the goal to significantly improve treatment outcomes for many patients, including those with vascular disease and those requiring hemodialysis. The company’s proprietary technologies are designed to create off-the-shelf products that, once approved, can be utilized in any patient. The company web site is

All statements, other than statements of historical fact, included in this announcement are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “will”, “anticipate”, “expect”, “believe”, “intend” and “should” or the negative of these terms or other comparable terminology. These statements relate to future events or Humacyte’s clinical development programs, reflect management’s current beliefs and expectations and involve known and unknown risks, uncertainties and other factors that may cause Humacyte’s actual results, performance or achievements to be materially different. Except as required by law, Humacyte assumes no obligation to update these forward-looking statements.